Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi bullish on Inchcape ahead of FY results

(Sharecast News) - Citi has reiterated its 'buy' rating for Inchcape ahead of the automotive distributor's full-year results on 4 March, saying little upside is currently priced into the stock despite its strong growth prospects. "We believe that Inchcape has a unique opportunity to consolidate the automotive distribution market," said analyst Arthur Truslove.

Citi currently stands 6% above company-compiled consensus on an adjusted pre-tax profit level for 2025, predicting a figure of £525m, up from an estimated £446m in 2024 according to market forecasts.

Truslove highlighted that the stock trades at an enterprise value-to-EBIT ratio of just 5.7, on consensus forecasts - "only just above the minimum seen since the start of 2013 of 5.5x and vs an average of 8.4x over the same period".

"In our view, this does not fully reflect the quality of the business, and we believe that management has an opportunity at FY24 on 4 March to provide significant additional information and comfort," the analyst said.

Shares were 1.3% higher at 664p by 0959 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.